{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/background-information/risk-factors/","result":{"pageContext":{"chapter":{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors","depth":2,"htmlHeader":"<!-- begin field 23fb63ff-64f8-46a8-bd02-0e0099c46918 --><h2>What are the risk factors?</h2><!-- end field 23fb63ff-64f8-46a8-bd02-0e0099c46918 -->","summary":"","htmlStringContent":"<!-- begin item 21d62b0c-49a3-4b55-b23d-a31f3a7e14b4 --><!-- begin field 286f9227-fe46-45c7-8f22-e904e6dcd2c0 --><p><strong>Risk factors for type 2 diabetes include:</strong></p><ul><li>Obesity and inactivity<ul><li>People who are overweight or obese (especially with central obesity) and/or have inactive lifestyles are at increased risk for developing type 2 diabetes, as overeating and inactivity can exacerbate insulin resistance. Obesity accounts for 80–85% of the overall risk for developing type 2 diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Diabetes UK, 2019a</a>]. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li></ul></li><li>Family history<ul><li>People with a family history of diabetes are 2–6 times more likely to have diabetes than people without a family history. The risk of developing type 2 diabetes is about 15% if one parent has type 2 diabetes, and 75% if both parents have type 2 diabetes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Diabetes UK, 2020</a>].</li></ul></li><li>Ethnicity<ul><li>People of Asian, African, and Afro-Caribbean ethnicity are 2–4 times more likely to develop type 2 diabetes than white people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Diabetes UK, 2020</a>].</li></ul></li><li>History of gestational diabetes<ul><li>Women with a history of gestational diabetes have a seven-fold increased risk for developing type 2 diabetes later in life. Children born to mothers with gestational diabetes have a six-fold increased risk for developing type 2 diabetes.</li></ul></li><li><div>Diet</div></li><li><div>A low-fibre, high glycaemic index (GI) diet may increase the risk of being overweight or obese. High-GI foods contain carbohydrates that are broken down quickly and cause a rapid increase in blood glucose levels, such as sugary foods and drinks, white rice, white bread, and potatoes.</div></li><li><div>Drug treatments</div><ul><li><div>Statins, corticosteroids, and combined treatment with a thiazide diuretic plus a beta-blocker, can increase the risk for developing hyperglycaemia and type 2 diabetes.</div></li></ul></li><li>Polycystic ovary syndrome<ul><li>This increases the risk of non-diabetic hyperglycaemia and type 2 diabetes. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/polycystic-ovary-syndrome/\">Polycystic ovary syndrome</a> for more information.</li></ul></li><li><div>Metabolic syndrome</div><ul><li><div>Insulin resistance is commonly associated with the metabolic syndrome, defined as a combination of raised blood pressure, dyslipidaemia, fatty liver disease, central obesity, and a tendency to develop thrombosis. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension</a>, <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>, <a class=\"topic-reference external-reference\" href=\"/topics/non-alcoholic-fatty-liver-disease-nafld/\">Non-alcoholic fatty liver disease (NAFLD)</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</div></li></ul></li><li>Low birth weight for gestational age<ul><li>There is some evidence that preterm birth before 35 weeks of gestation is associated with an increased risk for type 2 diabetes developing in adult life [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Kajantie, 2010</a>].</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Candler, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Zeitler, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Diabetes UK, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">NICE, 2020a</a>]</p><!-- end field 286f9227-fe46-45c7-8f22-e904e6dcd2c0 --><!-- end item 21d62b0c-49a3-4b55-b23d-a31f3a7e14b4 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"52c6d376-183c-509a-b866-5f284378ada4","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}